Physician profile
Michael Q Lim
NPI 1497931836
$2,266.83
in general payments reported to CMS, 2019-2025
24 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $218 · 2021: $513 · 2022: $336 · 2023: $193 · 2024: $68.15 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $638.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $688.98 | 2019-2022 | |
| Sage Therapeutics, LLC | $310.59 | 2021-2025 | Zurzuvae |
| Lilly USA, LLC | $174.31 | 2022-2023 | Mounjaro, Trulicity |
| Daiichi Sankyo INC. | $167.53 | 2020-2021 | |
| Exeltis, USA INC. | $140.69 | 2021-2025 | Slynd |
| Coopersurgical, INC. | $82.03 | 2019-2025 | Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $75.97 | 2019-2022 | |
| Aspira Women'S Health INC | $67.63 | 2021 | |
| Therapeuticsmd, INC. | $64.62 | 2019 | |
| Evofem Biosciences, INC. | $60.19 | 2021-2025 | Solosec, Phexx, Phexxi |
| Ethicon US, LLC | $51.88 | 2019-2023 | Enseal |
| Supernus Pharmaceuticals, INC. | $42.63 | 2025 | Qelbree |
| Allergan, INC. | $41.92 | 2019-2020 | |
| Lupin INC. | $41.48 | 2019 | |
| Mayne Pharma Commercial LLC | $38.32 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $36.50 | 2025 | Veozah |
| Hologic Sales and Service, LLC | $33.32 | 2019-2024 | Aptima |
| Avion Pharmaceuticals | $32.55 | 2019-2020 | |
| Horizon Therapeutics Plc | $28.61 | 2020-2021 | |
| Duchesnay USA Incorporated | $19.81 | 2019 | |
| Roche Diagnostics Corporation | $18.81 | 2019 | |
| Millicent US INC | $18.19 | 2020 | |
| Scynexis, INC. | $15.90 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.